EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies

Zofia Pietrasik, Mikołaj Kapała, Joanna Pietrasik, Monika Stefaniak iD, Sebastian Szubert iD, Krzysztof Książek iD, Justyna Mikuła-Pietrasik iD

Cancers · 14.08.2026 · 18 (16) · 2623

DOI: 10.3390/cancers18162623 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 14.08.2026. Verfasst von Zofia Pietrasik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology of Aging and Civilization Diseases, Poznan University of Medical Sciences, Swiecickiego 4 Str., 60-781 Poznan, Poland. Die Arbeit nennt 327 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Epithelial ovarian cancer (EOC) remains a gynecologic malignancy with a poor prognosis, with a 5-year survival of approximately 29% in advanced-stage disease. Despite cytoreductive surgery and platinum- and taxane-based chemotherapy, most patients relapse within 2 years. Major therapeutic barriers include chemoresistance, molecular heterogeneity, and an immunosuppressive peritoneal microenvironment. This review summarizes emerging therapeutic strategies for EOC, their mechanisms of action, and their potential to overcome treatment resistance.

Methods

PubMed/MEDLINE was searched for preclinical studies, phase I–III clinical trials, systematic reviews, and meta-analyses addressing novel ovarian cancer therapies and resistance mechanisms.

Results

The review covers molecularly targeted therapies, immunotherapies, metabolic and epigenetic approaches, cellular and gene therapies, targeted drug-delivery systems, and locoregional and physical modalities. Strategies include PARP inhibitors, antiangiogenic agents, antibody–drug conjugates, pathway inhibitors, immune checkpoint inhibitors, cancer vaccines, adoptive cell therapies, metabolic and epigenetic modulators, CAR-T, CAR-NK, CRISPR/Cas9, HIPEC, PIPAC, ablation, photodynamic therapy, and sonodynamic therapy.

Conclusions

The clinical maturity of these approaches varies substantially. PARP inhibitors, antiangiogenic agents, selected antibody–drug conjugates, MAPK-directed therapy in LGSOC, and HIPEC in selected settings have the strongest clinical support. Most immune combinations, metabolic and epigenetic therapies, adoptive cell therapies, gene-editing approaches, and novel delivery or physical modalities remain early clinical or predominantly preclinical. Progress will depend on biomarker-guided patient selection, reassessment of evolving resistance mechanisms, and rational treatment sequencing and combinations.

Schlagwörter

Stichwörter der Autor:innen

CAR-THIPECPIPACchemoresistanceepigenetic therapiesimmunotherapymetabolic therapiesovarian cancertargeted therapiestumor microenvironment

Autor:innen und Institutionen

  • Department of Pathophysiology of Aging and Civilization Diseases, Poznan University of Medical Sciences, Swiecickiego 4 Str., 60-781 Poznan, Poland.
  • Medical University of Łódź, Al. T. Kościuszki 4 Str., 90-419 Lodz, Poland.
  • Institute of Health Sciences, Faculty of Medical Sciences, Prince Mieszko I Poznań Medical University of Applied Sciences, Bułgarska 55 Str., 60-320 Poznan, Poland.
  • Department of Gynecological Oncology, Institute of Oncology, University of Medical Sciences, 82/84 Szamarzewskiego Str., 60-569 Poznan, Poland.

ORCID-Profile: Monika Stefaniak, Sebastian Szubert, Krzysztof Książek, Justyna Mikuła-Pietrasik

Zitieren

APA

Pietrasik, Z., Kapała, M., Pietrasik, J., Stefaniak, M., Szubert, S., Książek, K., & Mikuła-Pietrasik, J. (2026). Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies. Cancers, 18(16), 2623. https://doi.org/10.3390/cancers18162623

Vancouver

Pietrasik Z, Kapała M, Pietrasik J, Stefaniak M, Szubert S, Książek K, et al. Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies. Cancers. 2026;18(16):2623. doi:10.3390/cancers18162623

BibTeX
@article{Pietrasik2026,
  author = {Pietrasik, Zofia and Kapała, Mikołaj and Pietrasik, Joanna and Stefaniak, Monika and Szubert, Sebastian and Książek, Krzysztof and Mikuła-Pietrasik, Justyna},
  title = {Overcoming Therapy Resistance in Ovarian Cancer: From Molecular Mechanisms to Emerging Therapeutic Strategies},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2623},
  doi = {10.3390/cancers18162623}
}
Kostenlos starten →